Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$57.88T
24h Vol:
$10.26B
Dominance:
MSFT:5.17%
Stocklytics Platform
BETA
Instrument logo  GKOS

Glaukos Corp

GKOS
52 / 100
$92.30arrow_drop_down-0.35%-$0.32

Performance History

Stocklytics logo
Key Stats
Open$92.22
Prev. Close$92.63
EPS-2.69
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.50B
PE Ratio-
LOWHIGH
Day Range91.38
93.13
52 Week Range44.26
97.24
Ratios
P/B Ratio9.46
Revenue$303.57M
Operating M. %-35.89%
Earnings$0.00
Earnings Growth %-30.39%
EBITDA Margin %-28.82%
ROE %-25.21%
EPS-2.69

Score Breakdown

52vs 52. Market Avg.

All Score 52 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

GKOSMARKET
Value2339
Quality4040
Ownership119
Growth6545
Dividends-38
check_circle

Glaukos Corp's Price growth average in the last 3 years of 12.83% is great compared to market average of 6.42%. This indicates GKOS could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$755.35
24H (%)arrow_drop_down-3.41%
24H ($)-$26.70
MARKET CAP$717.06B
PRICE$520.28
24H (%)arrow_drop_down-0.24%
24H ($)-$1.26
MARKET CAP$481.49B
PRICE$157.76
24H (%)arrow_drop_up0.77%
24H ($)$1.21
MARKET CAP$380.01B
PRICE$128.17
24H (%)arrow_drop_up0.30%
24H ($)$0.38
MARKET CAP$324.81B

About Glaukos Corp (GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Thomas William Burns
Headquarters
Aliso Viejo
Employees
783
Exchange
NYSE
add Glaukos Corp to watchlist

Keep an eye on Glaukos Corp

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Glaukos Corp's (GKOS) price per share?

The current price per share for Glaukos Corp (GKOS) is $92.3. The stock has seen a price change of -$0.33 recently, indicating a -0.36% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Glaukos Corp (GKOS)?

For Glaukos Corp (GKOS), the 52-week high is $97.24, which is 5.35% from the current price. The 52-week low is $44.26, the current price is 108.54% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Glaukos Corp (GKOS) a growth stock?

Glaukos Corp (GKOS) has shown an average price growth of 12.83% over the past three years. It has received a score of 74 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Glaukos Corp as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Glaukos Corp (GKOS) stock price performance year to date (YTD)?

As of the latest data, Glaukos Corp (GKOS) has a year-to-date price change of 19.75%. Over the past month, the stock has experienced a price change of -1.06%. Over the last three months, the change has been 44.47%. Over the past six months, the figure is 26.53%. Looking at a longer horizon, the five-year price change stands at 33.15%.

question_mark
Is Glaukos Corp (GKOS) a profitable company?

Glaukos Corp (GKOS) has a net income of -$129.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.65% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -35.89% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $303.57M, with a revenue growth rate of 7.32%, providing insight into the company's sales performance and growth. The gross profit is $229.67M. Operating income is noted at -$113.81M. Furthermore, the EBITDA is -$87.49M.

question_mark
What is the market capitalization of Glaukos Corp (GKOS)?

Glaukos Corp (GKOS) has a market capitalization of $4.5B. The average daily trading volume is 414.97K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.